BioXell completes IPO on SWX Swiss Exchange
Shares in BioXell SpA, an Italian biopharmaceutical company developing novel therapeutics for urology, inflammation and related disorders, successfully completed its initial public offering on the SWX Swiss Exchange.
Trading of shares in the Zurich, Switzerland-based firm began on June 22, under the symbol BXLN, and the company says it will use the proceeds of its IPO primarily to support ongoing and new clinical development, such as for its lead compound, elocalcitol, a vitamin D3 derivative which is in Phase II trials for the treatment of three distinct urological indications.
The offer price per ordinary share of BioXell was set at 44 Swiss francs and the bank syndicate, consisting of Credit Suisse as lead manager, Bank am Bellevue, Societe Generale Corporate & Investment Banking and Pacific Growth Equities placed a total of 1,313,100 new ordinary shares.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze